Glabellar Frown Lines Clinical Trial
Official title:
A Phase I/II Randomized, Double Blind, Active-controlled, Single Center Clinical Trial for Evaluation of Safety and Efficacy of ATGC-110, An Intramuscularly Administered Clostridium Botulinum Neurotoxin Type A, in Adult Patients With Moderate to Severe Glabellar Frown Lines
Verified date | July 2020 |
Source | ATGC Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Botox for a total of 12 weeks after the administration in treatment of glabellar frown lines.
Status | Completed |
Enrollment | 60 |
Est. completion date | April 30, 2020 |
Est. primary completion date | April 30, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male and female subjects aged between 19 to 65 years - Subjects assigned a glabellar line severity grade of 2 or greater (moderate) at maximum frown assessed by the Investigator - Subjects who provide written consent to voluntarily participate in the study after receiving and understanding a detailed explanation of the study Exclusion Criteria: - Subjects with diseases that may affect neuromuscular function, such as Myasthenia gravis, Lambert-Eaton syndrome, Amyotrophic lateral sclerosis, or motor neuropathy - Subjects with the history of eyelid paralysis or ptosis - Subjects with significant facial asymmetry - Individuals whose glabellar lines cannot be satisfactorily improved with physical methods since lines are not flattened even using hands - Subjects who have received medication that inhibits neuromuscular function within the 4 weeks prior to screening such as muscle relaxants, anticholinergics, benzodiazepines and similar drugs, benzamides, tetracycline antibiotics, lincomycin antibiotics, and aminoglycoside antibiotics - Subjects taking anticoagulants or antiplatelet agents (Use of low-dose aspirin (325 mg/day or less) to prevent blood clotting is allowed) - Subjects who have received aspirin or NSAIDs within 7 days prior to administration of the IP. - Subjects with skin abnormalities such as infection at the injection site, dermatopathy, or scars. - Subjects with the history of treatment of the glabellar region (including the forehead) such as face lifting, permanent implants, or fillers - Subjects who have received other procedures that may affect the assessment of the glabellar or forehead lines during the following periods: - Within 6 months of screening: facial plastic surgery such as tissue augmentation, brow lift, or dermal resurfacing. - Within 6 months of screening: injection of dermal fillers with hyaluronic acid as the main ingredient. - Within 12 months of screening: injection of dermal fillers with ingredients other than hyaluronic acid as the main ingredient. - Individuals planning a facial cosmetic procedure (skin fillers, photorejuvenation, chemical/mechanical peeling, etc.) during the study period. - Individuals who have received a botulinum toxin preparation within 5 months prior to screening or those who are expected to receive a botulinum toxin preparation for any other purpose than the indication of this study (glabellar lines). - Subjects with the history of excessive alcohol consumption or drug addiction - Individuals with an anxiety disorder or other significant psychiatric disorders (e.g., depression), which, in the Investigator's opinion, may affect study participation or objective assessment of efficacy outcomes - Individuals who answered "yes" to any of the questions on the Columbia University Suicide Severity Rating Scale (C-SSRS) regarding a case within the past 12 months at the screening - Female subjects of childbearing age who do not agree to practice contraception using medically allowed contraceptive methods during the study period (hormonal contraception, IUD (intrauterine device) or IUS (intrauterine system), tubal ligation, dual protection (using a combination of male condom, female condom, cervical cap, contraceptive diaphragm, or contraceptive sponge) - Pregnant or lactating women - Subjects who are allergic or sensitive to the IP or its components - Individuals with concomitant illnesses that make them unsuitable for participation in the study by the Investigator such as malignant tumors, immunodeficiency (immune deficiency), kidney disease, liver disease, or lung disease - Individuals who have participated in other clinical trials within 3 months prior to participating in this study and have received an IP or medical device during the previous clinical studies - Individuals who are not eligible for this study for any reason as per the Investigator's discretion |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Nowon Eulji Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
ATGC Co., Ltd. |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Glabellar line improvement rate at maximum frown confirmed with investigator's live assessment | Changes in the glabellar line severity at maximum frown from baseline to 4 weeks after the IP administration were evaluated by investigator | 0 and 4 weeks after the administration | |
Secondary | Glabellar line improvement rate at maximum frown confirmed by investigator's live assessment | Changes in the glabellar line severity at maximum frown from baseline to 8 and 12 weeks after the IP administration were evaluated by investigator | 0, 8, 12 weeks after the administration | |
Secondary | Glabellar line improvement rate at rest confirmed by investigator's live assessment | Changes in the glabellar line severity at rest from baseline to 4, 8 and 12 weeks after the IP administration were evaluated by investigator | 0, 4, 8, 12 weeks after the administration | |
Secondary | Glabellar line improvement rate at rest confirmed by subject's assessment | Changes in the glabellar line severity at rest from baseline to 4, 8 and 12 weeks after the IP administration were evaluated by subjects | 0, 4, 8, 12 weeks after the administration | |
Secondary | Subject satisfaction rate | Subjects fill out the satisfaction questionnaire | 0, 4, 8, 12 weeks after the administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02236312 -
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
|
Phase 2 | |
Active, not recruiting |
NCT05565950 -
AI-09 In Subjects With Glabellar Lines, GL-101
|
Phase 1/Phase 2 | |
Completed |
NCT00430963 -
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
|
Phase 3 | |
Recruiting |
NCT05083286 -
Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines
|
Early Phase 1 | |
Completed |
NCT03687736 -
Subject Satisfaction With AbobutulinumtoxinA Treatment
|
Phase 4 | |
Active, not recruiting |
NCT04281745 -
Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®
|
Phase 4 | |
Active, not recruiting |
NCT05623410 -
Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
|
Phase 3 | |
Active, not recruiting |
NCT03440671 -
The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines
|
Phase 3 | |
Completed |
NCT03736928 -
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
|
Phase 2 | |
Completed |
NCT01808742 -
Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device
|
N/A | |
Completed |
NCT00777803 -
NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
|
Phase 3 | |
Completed |
NCT00430586 -
Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines
|
Phase 2 | |
Completed |
NCT05146999 -
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
|
Phase 3 | |
Completed |
NCT02428608 -
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
|
Phase 2 | |
Completed |
NCT04143815 -
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
|
Phase 2 | |
Not yet recruiting |
NCT05305768 -
Xeomin Treatment of Glabellar Lines Using OLD Versus COLD
|
Early Phase 1 | |
Completed |
NCT05364580 -
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
|
Phase 3 | |
Completed |
NCT05320393 -
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
|
Phase 2 | |
Completed |
NCT02677805 -
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
|
Phase 3 | |
Completed |
NCT01333397 -
Safety and Efficacy Study of Dysport RU and Glabellar Lines
|
Phase 2 |